Clinical Trial News Archive - May 2013
Get news by email or subscribe to our news feeds.
May 1, 2013
May 2, 2013
- Abide Therapeutics Announces Collaboration With Merck to Develop Novel Therapies for Type 2 Diabetes and Metabolic Diseases
- Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
- AcelRx Shares Positive Clinical Data for the Sufentanil NanoTab PCA System
- Algeta and Lumiphore Announce Further Expansion of Their Global Partnership for the Development of Targeted Alpha-pharmaceutical Cancer Therapeutics and Companion Diagnostics
- Gilead Reports Interim Data From Phase 2 LONESTAR Study
- Acceleron and Shire Conclude Collaboration on ACE-031
- Cardiome Accepts the Transfer of Sponsorship of U.S. and Canadian Vernakalant IV and Oral Regulatory Filings from Merck
May 3, 2013
- Big Pharma Preparing for a Pipeline Shopping Spree, Says GlobalData
- Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates
- Full Spectrum Genetics Receives Milestone Payment From Corporate Partner for Successfully Completing Therapeutic Protein Project
- Nymox Announces Completion of Patient Enrollment in Final Pivotal U.S. Phase 3 BPH Study
- MorphoSys Announces Clinical Milestone in Ophthalmology Program
May 6, 2013
- Bayer Provides Update on Phase II/III Trial of BAY 86-6150
- Bristol-Myer Squibb, AstraZeneca Drug Helps Lipodystrophy Patients
May 7, 2013
- Astellas, Drais Partner in Drug Development Deal
- EU Regulatory Authorities Grant Orphan Status to Eisai's Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
- Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer's Disease
- Pivotal Therapeutics Vascazen-Reveal Trial Meets Primary and Secondary Endpoints
- FDA Grants Fast Track Designation for Cubist’s Late-Stage Antibiotic Candidate
May 8, 2013
- Glaxo Reveals More About Sharing Drug Trial Data
- Amgen Announces Top-Line Results of Vectibix® (panitumumab) Phase 3 Head-to-Head Study Against Erbitux® (cetuximab) in Metastatic Colorectal Cancer
- Actelion provides update on Phase III GRIPHON study with selexipag in pulmonary arterial hypertension - Study continues
- Real-world data at ARVO highlight transformational outcomes seen with Lucentis
- Study: FOLFIRINOX followed by chemoradiation shows substantial activity in locally advanced pancreatic cancer
- Cell Medica Announces Treatment of First Pediatric Patient in Early Stage Clinical Trial of Cytovir ADV
- 13TH ANNUAL REPORT: Future blockbusters
- Eleven Biotherapeutics Presents Data on EBI-005, a Novel IL-1 Inhibitor Protein Therapeutic for Topical Treatment of Dry Eye Disease
May 9, 2013
- Trevena, Inc. and Forest Laboratories Announce a Collaborative Agreement For Development of TRV027 for the Treatment of Acute Heart Failure
- Acucela and Otsuka Pharmaceutical Announce Phase IIa Clinical Results of Emixustat Hydrochloride (ACU-4429) in Patients with Geographic Atrophy (GA) Associated with Dry Age-related Macular Degeneration (AMD)
- Operating Without Interrupting Warfarin Dramatically Reduces Risk of Bleeding Complications After Cardiac Device Surgery
- Galena Biopharma Poster Presentation at the American Pain Society 32nd Annual Scientific Meeting
- Kala Presents Data on Enhanced Topical Ocular Delivery of a Receptor Tyrosine Kinase Inhibitor
May 10, 2013
- Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma
- Isis Pharmaceuticals Earns $3.5 Million from Biogen Idec
- CytRx Discontinues Phase IIb Lung Cancer Trial
- Ferumoxytol Results in Significant Hemoglobin Increases in Adult Iron Deficiency Anemia Patients With Abnormal Uterine Bleeding Who Had Failed or Could Not Tolerate Oral Iron Therapy
May 13, 2013
- First-in-class Fycompa Pooled Pivotal Phase III Data Published in Epilepsia
- U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
- FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor VIII Therapy for Hemophilia A
- Neovasc Inc. Completes Enrollment in Cosira Trial
- MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in Non-Hodgkin's Lymphoma
- New Anti-Cocaine Vaccine Research Shows Drug Can't Reach the Brain, Human Clinical Trials on the Horizon
May 14, 2013
- AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
- Halo Pharma And Altus Formulation Announce New Formal Collaboration
- Rib-X Pharmaceuticals Initiates Delafloxacin Global Phase 3 Clinical Trial in Patients with Acute Bacterial Skin and Skin Structure Infections
- Inovio Pharmaceuticals DNA Vaccine Against Ebola and Marburg Filoviruses Provides Complete Protection in Preclinical Challenge Study
- Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
- Suneva Medical Announces Results of Its Pivotal ArteFill Acne Scar Study
- Cempra, Inc. Signs Exclusive License and Development Agreement for Solithromycin
May 15, 2013
- Bayer Initiates Phase III Trial of Stivarga (regorafenib) Tablets in Patients with Advanced Liver Cancer
- Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
- Ultragenyx Advances Clinical Development of UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7)
- Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohn's Disease
- Soligenix Starts Phase I Trial for SGX203 in Pediatric Crohn's Disease
May 16, 2013
- AstraZeneca Issues Update on Accelerated Oncology Pipeline in Advance of 2013 ASCO Annual Meeting
- Roche's obinutuzumab (GA101) significantly reduced the risk of disease progression or death in people with one of the most common forms of blood cancer
- Lung Cancer, Not One Disease: Diverse Patients Need Personalized Treatments, Two New Studies Show
- Nuvo Research Presents at the Annual Meeting of the American Association of Immunologists
- Merck KGaA: Detailed Results of Phase III Trial of L-BLP25 in Patients With Non-Small Cell Lung Cancer (START) to be Presented at ASCO
- AnaptysBio Awarded U.S. Government Contract To Develop Anti-Ricin Antibodies
- Novelos Therapeutics Provides Product Pipeline Update
- NW Bio Initiates Phase III DCVax®-L Brain Cancer Trial In Europe: King's College Hospital In The UK Is First Site To Open
- Gilead Announces Response Data from Phase 2 Study of Idelalisib for Previously Untreated Chronic Lymphocytic Leukemia
- Helsinn Group and Eisai Inc. Announce Top-Line Results for Pivotal Studies of the Investigational Fixed-Dose Combination of Netupitant and Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
- Markey, House Dems Introduce Bill to Protect Human Subjects in Clinical Trials
- Chimerix’s CMX001 Resistance Data Presented at the 26 th International Conference on Antiviral Research
- Chimerix's CMX001 Resistance Data Presented at the 26th International Conference on Antiviral Research
- Nuvo Research Announces Scientific Presentation at the Annual Meeting of the American Association of Immunologists
- Stallergenes and DBV Technologies enter into partnership for the development of innovative treatment of respiratory allergies Partnership to develop immunotherapy treatments for respiratory allergies using DBV’s skin patch, Viaskin
May 17, 2013
- New Study Shows Effect of Neupro (Rotigotine Transdermal System) on Cardiovascular Measures in Patients with Restless Legs Syndrome
- AbbVie, Galapagos Extend GLPG0634 Collaboration
- Sanofi's Myelofibrosis Phase III Trial Meets Endpoint
May 20, 2013
- Takeda And Lundbeck Present Results From Pivotal Phase 3 Clinical Trials With Vortioxetine, An Investigational Compound For Major Depressive Disorder
- Vortioxetine clinical phase III data show significant improvement in symptoms of major depression
- XenoPort Reports Top-Line Results of Phase 3 Trial of Arbaclofen Placarbil for Spasticity in Multiple Sclerosis Patients
- Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
- Intercept Pharmaceuticals Announces Positive Initial Results from Chronic Bile Acid Diarrhea Trial
- Healthcare Providers at Lilly Play Important Role in Helping Patients
- Cempra Presents Post-Phase II Analysis of Solithromycin's Efficacy and Safety
- Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S.
- Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes
- TRACON Pharmaceuticals Announces TRC105 Clinical Trials, Abstract Presentations at 2013 ASCO Annual Meeting
- Sangamo BioSciences Presents New Data From In Vivo Protein Replacement Platform For Development Of ZFP Therapeutics® For Monogenic Diseases
- Neuralstem ALS Trial Principal Investigator Presents Phase I Data
- Study: Few Patient-Reported Outcomes Are Included in Diabetes Clinical Trials
- Asmacure Highlights Four Presentations on Novel Pulmonary Development Compound ASM-024 Presented at American Thoracic Society 2013 International Conference
- Novozymes Biopharma’s recombinant human albumin helps innovative dry eye therapy move into clinical trials
May 21, 2013
- Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility
- Synageva's Sebelipase Alfa Receives Breakthrough Therapy Designation
- Janssen Phase III Hepatitis C Drug Shows Sustained Virologic Response
- New Data Reinforces Strength of Novartis Once-Daily COPD Portfolio
- Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma
- How Safe Are Prescription Drug Doses if Patients in Clinical Trials Did Not Take the Full Dose?
- Synergy Pharmaceuticals Presents Plecanatide Results From a Large Multicenter Clinical Study at Late-Breaking Abstract Session During Digestive Disease Week 2013
May 22, 2013
- From Research Labs to Doctors' Offices, Health Care Providers at Lilly Play Important Role
- Glaxo in $200M Antibiotic Development Deal With U.S.
- UCB and IBM Collaborate to Personalize Care for Epilepsy Patients
- Prosonix Initiates Phase 2 Clinical Study with PSX1002
- Ferumoxytol Treatment Produced Significant Hemoglobin Increases
- ChemoCentryx Announces Phase I Data With CCX507
- Positive results from a phase Ia study with MIV-711 for the treatment of skeletal disorders
- Novartis drug Afinitor significantly extended time without disease progression in women with HER2 positive advanced breast cancer
- Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S.
- A*Star and Cytos Bring Singapore’s First Influenza Vaccine to Clinical Testing
- Sciclone and Zensun Enter Into A Licensing Agreement for Novel Chronic Heart Failure Drug Neucardin for the China Market
- Medigene publishes final results from phase II Investigator Initiated Trial of EndoTAG®-1 at ASCO 2013
May 23, 2013
- Takeda Begins Phase III Trial of Multiple Myeloma Drug
- Celgene Announces U.S. FDA Grants Priority Review for ABRAXANE® sNDA in Advanced Pancreatic Cancer
- Sanofi Showcases Commitment to Prostate Cancer Research at Genitourinary Cancer Symposium
- Lpath Initiates Dosing in First Proof-of-Concept Trial of Anti-Cancer Drug, ASONEP
- Pharming Announces New Data On Ruconest In Primate Model Of Delayed Graft Function (DGF)
- OncoGenex Announces Plans for the Initiation of the Cedar Clinical Trial
- First patient dosed in the Phase I/II study of Umecrine Mood’s candidate drug for premenstrual dysphoric disorder
- Clinical trial tests targeting prostate cancer treatment
- Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain
- Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients
- Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease
May 24, 2013
May 27, 2013
May 28, 2013
- Astellas Fungal Infection Drug Gets FDA Orphan Drug Designation
- Study: Ipilimumab shows durable responses but low overall response rate in patients with unresectable or metastatic mucosal melanoma
- Invivis Pharmaceuticals to Present Positive Data Supporting A New Biomarker Predicting the Efficacy of Current Hormone Therapies in Early Breast Cancers at Asco 2013 Annual Meeting
- Medigene gains SynCore as global EndoTAG-1 partner and strategic core investor
- Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no major tolerability issues
- Soricimed Biopharma Inc. Announces U.S. Trial Site for Phase I Clinical Trial of New Cancer Drug, SOR-C13
- FDA Recommends Running Phase 2b Trial of Proellex-V in the Treatment of Severe Menstrual Bleeding Associated With Uterine Fibroids
- Grünenthal Group and Purdue Pharma L.P. Enter Into a Licensing Agreement
May 29, 2013
- Biovista and CFIDS Association of America Reach Milestone with Pre-IND Meeting
- Novartis Shares New Findings with 170 Abstracts at ASCO and EHA
- GSK and Genmab Announce Positive Top-Line Results for Arzerra
- Targacept Announces Initiation of Phase 2b Study of TC-5214 in Overactive Bladder
- Cyclopharm Limited Important Milestones in Nuclear Medicine
May 30, 2013
- Oncothyreon and Array to Develop and Market ARRY-380
- Study: Lilly's Forteo Increases Bone Mineral Density in Men
- New European Phase II Trial to Test Immunovaccine’s DPX-Survivac In Brain Cancer Patients
- Idenix Pharmaceuticals Announces Initiation of Phase II All-Oral Combination Study of Samatasvir and Simeprevir
- Oramed Pharmaceuticals Awarded Grant by the Office of the Chief Scientist of Israel
- Vosaroxin Review Published in Expert Opinion on Pharmacotherapy
- Achillion Nominates ACH-3422 as Nucleotide for the Treatment of Chronic HCV
- Amarin Announces Additional Effects of Vascepa
